| Ytd | 20.90% | |
| 1y | 24.16% |
| Open | 10.60 | Prev Close | 12.90 | Low | 10.50 | High | 12.99 | Mkt Cap | 68.94M |
| Vol | 0.00 | Avg Vol | 15.52K | EPS | 0.21 | P/E | 10.38 | Forward P/E | N/A |
| Beta | -0.40 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 09-26 | 50-d Avg | 12.31 | 200-d Avg | 11.07 | 1yr Est | 0.00 |
Business combination transaction with Voyager Acquisition Corp. complete, creating a Nasdaq-listed,
The business combination of VERAXA Biotech and Voyager Acquisition Corp. was closed successfully and
US stock futures lower, Nasdaq down 1%. Super Micro shares down 8.6% after announcing $7B offering t
Transactions Provide Financial Flexibility to Advance Pipeline of Next Generation Cancer Therapies C
U.S. stocks were higher, with the Dow Jones gaining over 350 points on Wednesday. GE Vernova shares
Dow Jones up 200 points, Avanos Medical Inc rose on going-private deal. Big gainers include AVNS, TV
Olaplex Holdings shares surge 51% after being acquired by Henkel AG & Co. KGaA. Other big gainer
Five Below Inc (FIVE) shares rose 7.2% in pre-market trading after reporting better-than-expected Q4
Voyager Acquisition Corporation (NASDAQ: "VACHU," "VACH," "VACHW") ("Voy
BROOKLYN, N.Y., March 13, 2026 (GLOBE NEWSWIRE) -- Voyager Acquisition Corporation (NASDAQ: “VACHU,”
BROOKLYN, N.Y., March 11, 2026 (GLOBE NEWSWIRE) -- Voyager Acquisition Corporation (NASDAQ: “VACHU,”
Crossingbridge Advisors LLC acquired a new position in shares of Voyager Acquisition Corp. (NASDAQ:
VERAXA shareholders approve merger & issuance of new shares to Voyager. Both resolutions are prerequ
Blaize (NASDAQ: BZAI - Get Free Report) and Voyager Acquisition (NASDAQ: VACH - Get Free Report) are
NEW YORK , Oct. 21, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & As
Partnership combines Secarna's OligoCreator® platform with VERAXA's technology suite to create next-
ZURICH, July 17, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA” or the "Company"), an emerging
ZURICH, SWITZERLAND, July 17, 2025 -- VERAXA Biotech AG (“VERAXA” or the "Company"), an emerging lea
VERAXA Attending ASCO and BIO with Cantor Fitzgerald, Voyager's Recently Retained Capital Markets Ad
VERAXA Attending ASCO and BIO with Cantor Fitzgerald, Voyager's Recently Retained Capital Markets Ad
Industry Veteran to Support Acceleration of Key Pipeline Projects and Novel BiTAC™ Antibody Formats